SAT2

Across TCGA pan-cancer cohorts, SAT2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SAT2 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher SAT2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SAT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRP, UCEC, and SKCM are the cancer types where SAT2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.040	0.896	<.001	36	view →
UCEC	DFS	Median	III,IV	1.000	0.534	.026	16	view →
SKCM	DFS	Median	II,III,IV	0.209	0.682	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SAT2–KIRP (DFS)

Open the KIRP breakdown →